Table 2. Overall survival from the timepoint of NEPC diagnosis in different subgroups.
| Median OS [months] | p | ||
|---|---|---|---|
| Histology | Small cell | 15.5 | 0.828 |
| Non-small cell | 17.1 | ||
| Mixed differentiation | Yes | 15.5 | 0.970 |
| No | 17.3 | ||
| Prior adenocarcinoma | Yes | 5.4 | 0.005 |
| No | 32.7 | ||
| Ki67 | ≥ 55 % | 10.4 | 0.325 |
| < 55 % | 17.1 | ||
| PSA | > ULN | 10.7 | 0.719 |
| ≤ ULN | 33.1 | ||
| NSE | > ULN | 9.6 | 0.105 |
| ≤ ULN | NR | ||
| CgA | > ULN | 15.5 | 0.330 |
| ≤ ULN | 9.6 | ||
| LDH | > ULN | 5.4 | 0.064 |
| ≤ ULN | 17.3 | ||
| Stage | Localized | 32.7 | 0.411 |
| Metastatic | 15.5 | ||
| Visceral metastases | Yes | 13.5 | 0.166 |
| No | NR | ||
| Palliative systemic therapy | Yes | 17.4 | 0.192 |
| No | 3.9 |